State of Alaska epidemiology bulletin: Recommended immunization schedule for children aged 7-18 years--Alaska, 2008

2008 ◽  
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kamel A. Samara ◽  
Hiba J. Barqawi ◽  
Basant H. Aboelsoud ◽  
Moza A. AlZaabi ◽  
Fay T. Alraddawi ◽  
...  

AbstractAnnually, 1.5 million cases of hepatitis A infection occur worldwide. The United Arab Emirates (U.A.E.) has seen a decrease in infection rates and seroprevalence coupled with an increase in the average age of infection. This study aimed to assess the U.A.E. society’s hepatitis A knowledge, and attitudes and vaccination practices, with the applicability of its introduction into the local immunization schedule. A self-administered, 50-item questionnaire was used to collect data from the four most populous cities in the U.A.E., between January and March 2020. A total of 458 responses were collected and analysed using IBM-SPSS-26, R-4.0.0 and Matplotlib-v3.2.1. Females had better attitudes (P = 0.036), practices (P < 0.0005), immunization schedule knowledge (AOR = 3.019; CI 1.482–6.678), and appreciation of the immunization schedule (AOR = 2.141; CI 1.310–3.499). A higher level of perceived knowledge was associated with an actual better knowledge (P < 0.0005), better practices (P = 0.011), and increased willingness to get vaccinated (AOR = 1.988; CI 1.032–3.828). Respondents were more likely to vaccinate their children against HAV if the vaccine were introduced into the National Immunization Program (P < 0.0005). Overall, disease knowledge was lacking but with positive attitudes and poor practices. There is high trust in the National Immunization Program and a potential for improving poor practices through local awareness campaigns.


2000 ◽  
Vol 68 (7) ◽  
pp. 4312-4318 ◽  
Author(s):  
Sanchita Chatterjee ◽  
Subhash Singh ◽  
Rashmi Sohoni ◽  
Nevil J. Singh ◽  
Akhil Vaidya ◽  
...  

ABSTRACT Antibodies against the Plasmodium falciparum P0 ribosomal phosphoprotein (PfP0) have been detected exclusively but extensively in malaria-immune persons. Polyclonal rabbit and mice sera were raised against two recombinant polypeptides of P. falciparum P0 protein, PfP0N and PfP0C, covering amino acids 17 to 61 and the remaining amino acids 61 to 316, respectively. Sera against both these domains detected a 35-kDa protein fromPlasmodium yoelii subsp. yoelii, a rodent malarial parasite, and stained the surface of merozoites in immunofluorescence assays. Total immunoglobulin G (IgG) purified from rabbit and mouse anti-PfP0 sera by ammonium sulfate and DEAE-cellulose chromatography was used for passive transfer experiments in mice. Mice passively immunized with both anti-PfP0N and anti-PfP0C showed distinctly lower levels of parasitemia than control mice. With immunizations on days −1, 0, 1, 3, and 5, about 50% of both sets of mice receiving anti-PfP0N and anti-PfP0C cleared the lethal 17XL strain of P. yoelii and revived by day 25. All the control mice died by day 10. By extending the immunization schedule, the survival period of the mice could be extended for every mouse that received anti-PfP0 IgG. These data demonstrate the cross-protection of the anti-PfP0 IgG and establish parasite P0 protein as a target for invasion-blocking antibodies.


Vaccine ◽  
2012 ◽  
Vol 30 (24) ◽  
pp. 3489-3491 ◽  
Author(s):  
Gregory A. Poland ◽  
Diane Peterson ◽  
Pierce Gardner

PEDIATRICS ◽  
1996 ◽  
Vol 97 (1) ◽  
pp. 143-143
Author(s):  

The Recommended Childhood Immunization Schedule for 1995 was developed by the Committee on Infectious Diseases (COID) of the American Academy of Pediatrics in collaboration with the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) and the American Academy of Family Physicians (AAFP).1 Since the January 1995 publication, the AAP, ACIP, and AAFP have agreed on the following revisions: 1. The revised schedule is dated January-June 1996 and will be reprinted in July 1996 with any indicated changes. Incorporating dates in the chart will assure health care providers that they are using the most current schedule. 2. A column has been added to indicate that the second dose of hepatitis B vaccine can be administered at 1 month of age, provided that at least 1 month has elapsed since the first dose was given. Also, the doses of vaccine are provided in micrograms by individual product instead of volume, as several different concentrations of recombivax-HB (Merck, Sharp and Dohme) vaccine are available. 3. A bar has been added at 11-12 years of age to indicate that adolescents who have not previously received three doses of hepatitis B vaccine should initiate or complete the three-dose series. 4. Varicella zoster virus vaccine (Var) has been added to the schedule. In addition to the previously issued Academy recommendations, answers to commonly asked questions are addressed in a recent AAP News article.2,3 5. Information on inactivated poliomyelitis vaccine (IPV) has been added to reflect the Academy's current policy.


Sign in / Sign up

Export Citation Format

Share Document